NervGen Pharma Corp. (NGEN) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 23, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 40-F for FY2025, filed Mar 31, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the NGEN SEC filings page.
This page shows NervGen Pharma Corp. (NGEN) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 2 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
NervGen Pharma Corp. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
NervGen Pharma Corp. passes 2 of 5 computable financial strength tests (4 of the nine could not be computed from available data). 1 of 4 profitability signals pass, all 1 leverage/liquidity signals pass.
NervGen Pharma Corp. reported a net loss of $32.2M while operations used $14.2M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
NervGen Pharma Corp. reported a net loss of $32.2M in fiscal year 2025. The change from the prior year is not meaningful, because that figure was zero or negative.
NervGen Pharma Corp. earned -$0.44 per diluted share (EPS) in fiscal year 2025. The change from the prior year is not meaningful, because that figure was zero or negative.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Cash & Balance Sheet
NervGen Pharma Corp. held $16.1M in cash as of fiscal year 2025; no long-term debt figure is on record for that period.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
NervGen Pharma Corp.'s ROE was -1268.9% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 327.7 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
NervGen Pharma Corp. invested $10.1M in research and development in fiscal year 2025. This represents a decrease of 7.6% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
NGEN Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, SG&A Expenses, Operating Income, EBITDA, Income Tax.
NGEN Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2540-F | FY2440-F |
|---|---|---|
| Total Assets | $16.9M+25.1% | $13.5M |
| Current Assets | $16.6M+25.9% | $13.2M |
| Cash & Equivalents | $16.1M+34.2% | $12.0M |
| Accounts Receivable | $59K-79.6% | $288K |
| Total Liabilities | $14.4M+22.6% | $11.7M |
| Current Liabilities | $14.4M+22.6% | $11.7M |
| Non-Current Liabilities | $0-100.0% | $6K |
| Total Equity | $2.5M+41.7% | $1.8M |
| Retained Earnings | -$107.0Mn/m | -$71.3M |
Not reported in any period shown, so not listed: Short-Term Investments, Inventory, Long-Term Investments, Goodwill, Long-Term Debt.
NGEN Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Depreciation & Amortization, Stock-Based Compensation, Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.
NGEN Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Debt-to-Equity, Asset Turnover, FCF Margin.
Where NervGen Pharma Corp. Ranks
Frequently Asked Questions
Is NervGen Pharma Corp. profitable?
No, NervGen Pharma Corp. (NGEN) reported a net loss of $32.2M in fiscal year 2025.
What is NervGen Pharma Corp.'s return on equity (ROE)?
NervGen Pharma Corp. (NGEN) has a return on equity of -1268.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is NervGen Pharma Corp.'s operating cash flow?
NervGen Pharma Corp. (NGEN) recorded an outflow of $14.2M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are NervGen Pharma Corp.'s total assets?
NervGen Pharma Corp. (NGEN) had $16.9M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does NervGen Pharma Corp. spend on research and development?
NervGen Pharma Corp. (NGEN) invested $10.1M in research and development during fiscal year 2025.
What is NervGen Pharma Corp.'s current ratio?
NervGen Pharma Corp. (NGEN) had a current ratio of 1.16 as of fiscal year 2025, which is considered adequate.
What is NervGen Pharma Corp.'s liabilities-to-equity ratio?
NervGen Pharma Corp. (NGEN) had a liabilities-to-equity ratio of 5.68 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.
What is NervGen Pharma Corp.'s return on assets (ROA)?
NervGen Pharma Corp. (NGEN) had a return on assets of -190.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is NervGen Pharma Corp.'s P/E ratio?
NervGen Pharma Corp. (NGEN) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $153.8M as of Oct 23, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is NervGen Pharma Corp.'s price-to-sales ratio?
NervGen Pharma Corp. (NGEN) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $153.8M as of Oct 23, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is NervGen Pharma Corp.'s Piotroski F-Score?
NervGen Pharma Corp. (NGEN) has a Piotroski F-Score of 2 out of 5 computable signals; 4 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are NervGen Pharma Corp.'s earnings high quality?
NervGen Pharma Corp. (NGEN) reported a net loss of $32.2M while operations used $14.2M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.